User profiles for Daniel O. Clegg
 | Daniel OM CleggUniversity of Utah Verified email at hsc.utah.edu Cited by 15846 |
[HTML][HTML] Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Background Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The
multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis …
multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis …
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial
Objective To determine the safety and efficacy of etanercept in a multicenter, randomized,
placebo‐controlled, double‐blind trial of adults with moderate to severe active ankylosing …
placebo‐controlled, double‐blind trial of adults with moderate to severe active ankylosing …
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study
Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective
for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory …
for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory …
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of …
… Clegg, MD: Salt Lake City Department of Veterans Affairs Medical Center, and University of
Utah… Address reprint requests to Daniel O. Clegg, MD, University of Utah School of Medicine, …
Utah… Address reprint requests to Daniel O. Clegg, MD, University of Utah School of Medicine, …
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial
…, RW Moskowitz, HJ Williams, DO Clegg - … : Official Journal of …, 2008 - Wiley Online Library
Objective Osteoarthritis (OA) of the knee causes significant morbidity and current medical
treatment is limited to symptom relief, while therapies able to slow structural damage remain …
treatment is limited to symptom relief, while therapies able to slow structural damage remain …
Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial
…, R Neuner, DA Kaplan, DO Clegg… - Annals of internal …, 1995 - acpjournals.org
Objective: To assess the safety and efficacy of minocycline in the treatment of rheumatoid
arthritis. Design: A double-blind, randomized, multicenter, 48-week trial of oral minocycline (…
arthritis. Design: A double-blind, randomized, multicenter, 48-week trial of oral minocycline (…
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from …
…, RW Moskowitz, HJ Williams, DO Clegg - Annals of the …, 2010 - ard.bmj.com
Background Knee osteoarthritis (OA) is a major cause of pain and functional limitation in
older adults, yet longer-term studies of medical treatment of OA are limited. Objective To …
older adults, yet longer-term studies of medical treatment of OA are limited. Objective To …
Treatment of rheumatoid arthritis with oral type II collagen: results of a multicenter, double‐blind, placebo‐controlled trial
…, JM Kremer, EW St. Clair, DO Clegg… - … : Official Journal of …, 1998 - Wiley Online Library
Objective Oral administration of cartilage‐derived type II collagen (CII) has been shown to
ameliorate arthritis in animal models of joint inflammation, and preliminary studies have …
ameliorate arthritis in animal models of joint inflammation, and preliminary studies have …
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study
Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is
effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with …
effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with …
[PDF][PDF] A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases
Rheumatoid arthritis (RA) is an autoimmune/inflammatory disorder with a complex genetic
component. We report the first major genomewide screen of multiplex families with RA …
component. We report the first major genomewide screen of multiplex families with RA …